Bristol-Myers Squibb Company (BMY)’in fiyatı nedir?

Bristol-Myers Squibb Company (BMY)’in fiyatı $62.26’dir

Bristol-Myers Squibb Company (BMY)’in piyasa değeri nedir?

Bristol-Myers Squibb Company (BMY)’in piyasa değeri $127.18B’dir.

Bristol-Myers Squibb Company (BMY) Tedavüldeki Hisseler

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Yıl	Tedavüldeki Hisse Sayısı	Değiştir
2026 (TTM)	2.04B	0.05%
2025	2.04B	0.69%
2024	2.03B	-2.03%
2023	2.07B	-2.86%
2022	2.13B	-4.10%
2021	2.22B	-1.64%
2020	2.26B	32.43%
2019	1.71B	4.41%
2018	1.63B	-0.73%
2017	1.65B	-1.56%
2016	1.67B	0.24%
2015	1.67B	0.60%
2014	1.66B	0.79%
2013	1.64B	-1.56%
2012	1.67B	-1.76%
2011	1.70B	-0.76%
2010	1.71B	-13.22%
2009	1.97B	-0.15%
2008	1.98B	0.36%
2007	1.97B	0.51%
2006	1.96B	0.41%
2005	1.95B	0.51%
2004	1.94B	0.26%
2003	1.94B	-3.01%
2002	2.00B	2.95%
2001	1.94B	-1.27%
2000	1.97B	0.00%

Yıl

Tedavüldeki Hisse Sayısı

Değiştir

2026 (TTM)

2.04B

0.05%

2025

2.04B

0.69%

2024

2.03B

-2.03%

2023

2.07B

-2.86%

2022

2.13B

-4.10%

2021

2.22B

-1.64%

2020

2.26B

32.43%

2019

1.71B

4.41%

2018

1.63B

-0.73%

2017

1.65B

-1.56%

2016

1.67B

0.24%

2015

1.67B

0.60%

2014

1.66B

0.79%

2013

1.64B

-1.56%

2012

1.67B

-1.76%

2011

1.70B

-0.76%

2010

1.71B

-13.22%

2009

1.97B

-0.15%

2008

1.98B

0.36%

2007

1.97B

0.51%

2006

1.96B

0.41%

2005

1.95B

0.51%

2004

1.94B

0.26%

2003

1.94B

-3.01%

2002

2.00B

2.95%

2001

1.94B

-1.27%

2000

1.97B

0.00%

Şirket	Tedavüldeki Hisse Sayısı	Fark	Ülke
Eli Lilly and Company LLY.US	892.40M	-56.30%	US
Johnson & Johnson JNJ.US	2.44B	19.50%	US
AbbVie Inc. ABBV.US	1.77B	-13.27%	US
Roche Holding AG RO.SW	796.00M	-61.02%	CH
Merck & Co., Inc. MRK.US	0.00	-100.00%	US

Şirket

Tedavüldeki Hisse Sayısı

Fark

Ülke